Oncotarget

Research Papers:

In vivo manipulation of the protein homeostasis network in rhabdomyosarcoma

Kristen Kwong, Yue Pan, Jacqueline Morales, Matthew Watson, David V. Allegakoen, Alex G. Lee, Trever G. Bivona, Peter Wipf, Christopher J. Guerriero, Jeffrey L. Brodsky and Amit J. Sabnis _

PDF  |  Full Text  |  Supplementary Files  |  How to cite  |  Press Release

Oncotarget. 2025; 16:681-696. https://doi.org/10.18632/oncotarget.28764

Metrics: PDF 90 views  |   Full Text 295 views  |   ?  


Abstract

Kristen Kwong1, Yue Pan1, Jacqueline Morales1, Matthew Watson1, David V. Allegakoen1,2, Alex G. Lee1, Trever G. Bivona3,4, Peter Wipf5, Christopher J. Guerriero6, Jeffrey L. Brodsky6 and Amit J. Sabnis1

1 Department of Pediatrics, Division of Oncology, University of California San Francisco, San Francisco, CA 94143, USA

2 Department of Pediatrics, Georgetown University, Washington, DC 20057, USA

3 Department of Medicine, Division of Hematology-Oncology, University of California San Francisco, San Francisco, CA 94143, USA

4 Chan Zuckerberg Biohub, San Francisco, CA 94158, USA

5 Department of Chemistry, University of Pittsburgh, Pittsburgh, PA 15260, USA

6 Department of Biological Sciences, University of Pittsburgh, Pittsburgh, PA 15260, USA

Correspondence to:

Amit J. Sabnis, email: [email protected]

Keywords: protein homeostasis; rhabdomyosarcoma; unfolded protein response; preclinical therapeutics; p97

Received: April 03, 2025     Accepted: August 14, 2025     Published: August 29, 2025

Copyright: © 2025 Kwong et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

The protein homeostasis (proteostasis) network includes quality control systems that coordinate protein synthesis, folding, localization, and degradation, and is deregulated in numerous diseases including cancer. Loss of proteostasis can activate lethal cellular stress responses, potentially opening a therapeutic window. Previous research demonstrated that MAL3-101, an inhibitor of heat shock protein 70-kD (HSP70) chaperones, selectively induces rhabdomyosarcoma (RMS) cell death via unfolded protein response (UPR) activation. RMS is the most common pediatric soft tissue sarcoma, and relapsed patients are rarely cured despite transient responses to DNA-damaging therapy. To examine whether MAL3-101 or more drug-like proteostasis inhibitors represent a new therapeutic strategy for RMS, we screened proteostasis components that might recapitulate the effects of MAL3-101 in vivo. We find that inhibition of VCP, which encodes the p97 ATPase that facilitates proteasome-dependent degradation, similarly activates the UPR and induces RMS apoptosis. In mouse models, a preclinical p97 inhibitor showed superior bioavailability and anti-tumor activity compared to MAL3-101. Patient-derived xenografts exhibited a spectrum of p97 inhibitor sensitivities, and RNA sequencing of resistant tumors revealed elevated autophagy, nominating a biomarker of proteostasis adaptability. Together, these findings confirm that proteostasis inhibition can slow RMS growth and suggest that targeting compensatory network components might yield synergistic outcomes.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28764